Discrepancy between patient- and healthcare provider-reported adverse drug reactions in inflammatory bowel disease patients on biological therapy.

Published on Jun 2, 2021in United European gastroenterology journal3.549
· DOI :10.1002/UEG2.12107
Pepijn W. A. Thomas1
Estimated H-index: 1
(Radboud University Nijmegen),
Tessa E H Römkens13
Estimated H-index: 13
+ 5 AuthorsFrank Hoentjen16
Estimated H-index: 16
(Radboud University Nijmegen)
BACKGROUND Only limited data is available on the extent and burden of adverse drug reactions (ADRs) to biological therapy in inflammatory bowel disease (IBD) patients in daily practice, especially from a patient's perspective. OBJECTIVE The aim of this study was to systematically assess patient-reported ADRs during biological therapy in IBD patients and compare these with healthcare provider (HCP)-reported ADRs. METHODS This multicentre, prospective, event monitoring study enrolled IBD patients on biological therapy. Patients completed bimonthly comprehensive web-based questionnaires regarding description of biological induced ADRs, follow-up of previous ADRs and experienced burden of the ADR using a five-point Likert scale. The relationship between patient-reported ADRs and biological therapy was assessed. HCP-reported ADRs were extracted from the electronic healthcare records. RESULTS In total, 182 patients (female 51%, mean age 42.2 [standard deviation 14.2] years, Crohn's disease 77%) were included and completed 728 questionnaires. At baseline, 60% of patients used infliximab, 30% adalimumab, 9% vedolizumab and 1% ustekinumab. Fifty percent of participants reported at least one ADR with a total of 239 unique ADRs. Fatigue (n = 26) and headache (n = 20) resulted in the highest burden and a correlation in time with the administration of the biological was described in 56% and 85% respectively. Out of 239 ADRs, 115 were considered biological-related. HCPs reported 119 ADRs. Agreement between patient-reported ADRs and HCP-reported ADRs was only 13%. CONCLUSION IBD patients often report ADRs during biological therapy. We observed an important significant difference between the type and frequency of patient-reported ADRs versus HCP-reported ADRs, leading to an underestimation of more subjective ADRs and patients' ADR-related burden.
📖 Papers frequently viewed together
20213.15BMC Cancer
8 Authors (Ruofei Du, ..., Tao Wang)
#1Pepijn W. A. Thomas (Radboud University Nijmegen)H-Index: 1
#2Rachel L. WestH-Index: 16
view all 9 authors...
Purpose To assess the agreement between patient-reported and health care provider-reported medical information in inflammatory bowel disease (IBD). Methods This multicentre, prospective, event monitoring study enrolled adult Crohn's disease (CD) and ulcerative colitis (UC) patients treated with a biological in four medical centres in the Netherlands. At two-monthly intervals, patients completed questionnaires on biological use, combination therapy and indication. The patient-reported information...
#1Yuli Guzman-PradoH-Index: 3
#2Jennifer Ben Shimol (TAU: Tel Aviv University)H-Index: 2
Last. Ondrej SamsonH-Index: 3
view all 3 authors...
BACKGROUND As a result of the growing use of immune checkpoint inhibitors (ICIs) for treating malignancy, immune-related adverse events (irAEs) have been increasingly reported. Higher body mass index (BMI) has been highlighted as a potential risk factor for the development of irAEs. However, there are no meta-analyses summarizing the association between BMI and irAEs in patients on ICI therapies. METHODS PubMed, MEDLINE, EMBASE, Cochrane and grey literature were searched up to January 2020. Odds...
5 CitationsSource
#1L. KosseH-Index: 2
#2Naomi T. JessurunH-Index: 5
Last. Michael T. Nurmohamed (VUmc: VU University Medical Center)H-Index: 63
view all 7 authors...
OBJECTIVES: Assessment of the quality of patient-reported medical information in the Dutch Biologic Monitor and evaluation of the representativeness of the sampled participants. METHODS: Consecutive adult patients using a biologic DMARD (bDMARD) for an immune-mediated inflammatory disease were included in eight Dutch centres. For this substudy, data of 550 patients with inflammatory rheumatic diseases were used. Patient-reported bDMARD prescription, indication and combination therapy were verifi...
3 CitationsSource
#1Jette A. van LintH-Index: 1
#2Naomi T. JessurunH-Index: 5
Last. Bart J F van den BemtH-Index: 24
view all 12 authors...
INTRODUCTION Although the burden of adverse drug reactions (ADRs) has a significant impact on patients' quality of life, thorough knowledge about patients' perspectives on the burden of ADRs attributed to biologics is lacking. OBJECTIVES This study was conducted to gain insight into the patient burden of ADRs experienced with biologic use. METHODS The Dutch Biologic Monitor is a prospective, multicentre, event monitoring cohort system including information collected by web-based questionnaires f...
1 CitationsSource
#1Angelica Nocerino (Lenox Hill Hospital)H-Index: 2
#2Andrew A. Nguyen (Lenox Hill Hospital)H-Index: 1
Last. Arun Swaminath (Lenox Hill Hospital)H-Index: 17
view all 6 authors...
Fatigue is a burdensome, multidimensional, and multifactorial symptom that is associated with a wide array of chronic illnesses, specifically occurring in nearly 50% of patients with inflammatory bowel disease (IBD). Although common, given its subjective nature, physicians often under-recognize and undertreat this debilitating symptom. There are multiple etiologies that can contribute to fatigue in patients with IBD, including disease activity, anemia, medications, psychosomatic symptoms, and al...
5 CitationsSource
#1Sudabeh Alatab (Tehran University of Medical Sciences)H-Index: 15
#2Sadaf Ghajarieh Sepanlou (Shiraz University of Medical Sciences)
Last. Mohsen NaghaviH-Index: 142
view all 85 authors...
Summary Background The burden of inflammatory bowel disease (IBD) is rising globally, with substantial variation in levels and trends of disease in different countries and regions. Understanding these geographical differences is crucial for formulating effective strategies for preventing and treating IBD. We report the prevalence, mortality, and overall burden of IBD in 195 countries and territories between 1990 and 2017, based on data from the Global Burden of Diseases, Injuries, and Risk Facto...
191 CitationsSource
#2Bruna Cipriano Almeida Barros (UNIFESP: Federal University of São Paulo)H-Index: 3
Last. Luciane Cruz LopesH-Index: 18
view all 9 authors...
Background: Biological agents used for the treatment of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) are associated with serious adverse effects (SAEs). Although several biologics have demonstrated good efficacy and tolerability in short-term trials, treatment guidelines recommend them as third line therapies due to a relative lack of long-term safety data. Objective: To determine the frequency and severity of adverse effects associated with the long-term use of biologics in the treat...
10 CitationsSource
#1Tiziana LarussaH-Index: 13
#2Caterina PalleriaH-Index: 17
Last. Francesco LuzzaH-Index: 28
view all 13 authors...
#1Helen Yu (Stanford University)H-Index: 6
#2Donna MacIsaac (Stanford University)H-Index: 6
Last. K.T. Park (Stanford University)H-Index: 19
view all 8 authors...
SummaryBackground Real-world data quantifying the costs of increasing use of biologics in inflammatory bowel disease (IBD) are unknown. Aim To determine the outpatient IBD drug utilization trends, relative market share, and costs in the USA during a 9-year period. Methods The Truven MarketScan® Database was analysed for patients with Crohn's disease (CD) and ulcerative colitis (UC) during 2007-2015. National drug codes were used to identify prescription drugs; Healthcare Common Procedure Coding ...
68 CitationsSource
BACKGROUND: Although infliximab is an effective therapy for inflammatory bowel disease (IBD), it is associated with dermatological events and infusion reactions. It is not known whether a relationship between these adverse events (AEs) and infliximab trough levels (ITLs) exists.
17 CitationsSource
Cited By0